

Development of a non-clinical candidate for colorectal cancer treatment RACE-111 (EGFRX4-1BB) bispecific antibody



ONCOLOGY	Candidate
Product Type	Bispecific antibody
Indication	Colorectal Cancer (CRC)
Target	EGFR expressing in cancer and 4-1BB on cancer reactive T cell
MoA(Mechanism of Action)	RACE redirects EGFR positive cancer to CD8+ T cell in order to eliminate cancer
Competitiveness	Novel bispecific antibody platform with good manufacturability Strong CD8+ T cell stimulation compared to another bispecific format Tumor reactive T cell activation requires presence of EGFR+ cancer cell Lowering the risk of off-tumor toxicity (conditional agonist) Potent drug response in MSS CRC as well as MSI-H
Development Stage	Candidate
Route of Administration	Intravenous (IV)